FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj ...

The FDA granted accelerated approval for iberdomide combined with daratumumab, hyaluronidase-fihj, and dexamethasone to treat adults with relapsed or refractory multiple myeloma who have had prior therapies. The approval is based on enhanced efficacy in minimal residual disease-negative complete response shown in a Phase 3 trial.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.